Baxter BioPharma Solutions Announces Sterile Manufacturing Agreement for Novavax COVID-19 Vaccine
Baxter to provide fill-finish manufacturing services for Novavax' COVID-19 vaccine
Novavax and Baxter BioPharma Solutions have entered into a sterile manufacturing agreement for Novavax' COVID-19 vaccine.
The agreement will see Baxter provide fill-finish manufacturing services for Novavax' COVID-19 vaccine at its HalleWestfalen, Germany facility. Baxter's HalleWestfalen facility is a world-class manufacturing facility with over 60 years of experience in sterile medication production and delivery. The facility is ISO 14001-certified and has a proven track record of producing high-quality pharmaceuticals.
The agreement with Novavax is a significant win for Baxter and further strengthens the company's position as a leading provider of sterile manufacturing services. The agreement also represents a major milestone for Novavax, as it brings the company closer to commercializing its COVID-19 vaccine.
Baxter is committed to working with Novavax to ensure the successful production and delivery of its COVID-19 vaccine. The company is confident that its expertise and experience in sterile manufacturing will help Novavax to bring its vaccine to market quickly and safely.
تعليقات